These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27100411)

  • 1. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
    Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
    Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
    Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
    World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and external validation of a nomogram for predicting the conditional probability of survival after D2 lymphadenectomy for gastric cancer: A multicentre study.
    Chen QY; Zhong Q; Wang W; Desiderio J; Liu ZY; Xie JW; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Li P; Zheng CH; Zhou ZW; Parisi A; Huang CM
    Eur J Surg Oncol; 2019 Oct; 45(10):1934-1942. PubMed ID: 31027946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China.
    Liu K; Chen XZ; Zhang YC; Zhang WH; Chen XL; Sun LF; Yang K; Zhang B; Zhou ZG; Hu JK
    Surgery; 2021 Feb; 169(2):426-435. PubMed ID: 32950240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
    Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
    Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
    Wang ZX; Li GX; Zhou ZW; Huang ZP; Wang F; Xu RH
    Br J Surg; 2017 Aug; 104(9):1226-1234. PubMed ID: 28449182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer.
    Tai Q; Shao H; Liu Y; Li E; Zhao R
    J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
    Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
    Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of laparoscopic spleen-preserving splenic hilar lymphadenectomy on the surgical outcome of proximal gastric cancer: a propensity score-matched, case-control study.
    Huang CM; Chen T; Lin JX; Chen QY; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Cao LL; Lin M; Tu RH
    Surg Endosc; 2017 Mar; 31(3):1383-1392. PubMed ID: 27450211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application value of nomogram and prognostic factors of gastric cancer patients who underwent D2 radical lymphadenectomy.
    Mu GC; Huang Y; Liu ZM; Wu XH; Qin XG; Chen ZB
    BMC Gastroenterol; 2019 Nov; 19(1):188. PubMed ID: 31729975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer.
    Jiang Y; Li T; Liang X; Hu Y; Huang L; Liao Z; Zhao L; Han Z; Zhu S; Wang M; Xu Y; Qi X; Liu H; Yang Y; Yu J; Liu W; Cai S; Li G
    JAMA Surg; 2017 Jul; 152(7):e171087. PubMed ID: 28538950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience.
    Ghidini M; Donida BM; Totaro L; Ratti M; Pizzo C; Benzoni I; Lomiento D; Aldighieri F; Toppo L; Ranieri V; Senti C; Tanzi G; Martinotti M; Passalacqua R; Rovatti M; Tomasello G
    Clin Transl Oncol; 2020 Jul; 22(7):1004-1012. PubMed ID: 31599376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
    Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
    Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
    Lu W; Zeng X; Li N; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
    Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
    Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.